Leading experts discuss insights on advances in the treatment of glioblastoma.
This activity is intended for hematologists/oncologists, neurologists, radiologists, surgeons, and other healthcare professionals who treat patients with glioblastoma.
The goal of this activity is to highlight the current treatment paradigm for glioblastoma (GBM), discuss how emerging clinical trial data may alter the landscape and discuss the adverse event profiles of treatments.
Approximate Time to Complete: 30 minutes
Course Available Beginning: Mar. 23, 2017
Developed through a partnership between SITC and Medscape.
Upon completion of this activity, participants will be able to:
- Increased knowledge of how the treatment paradigm for GBM may soon change as a result of ongoing clinical trials
- Increased knowledge regarding the distinct safety profiles of agents being used in the management of GBM
- Increased knowledge regarding how clinical trial data on the use of emerging agents differ in the management of GBM